Abstract
Objective: Adiposity has been hypothesized to interfere with the activity of bevacizumab (BEV), an anti-angiogenic agent. Measurements of adiposity, BMI, surface fat area (SFA), and visceral fat area (VFA) were investigated as prognostic of oncologic outcomes among patients treated with chemotherapy, with or without BEV, on GOG 218, a prospective phase III trial. Method: Pretreatment computed tomography (CT) for 1538 GOG 218 participants were analyzed. Proportional hazards models assessed association between adiposity and overall survival (OS) adjusted for other prognostic factors. The predictive value of adiposity as a function of BEV treatment was assessed in 1019 patients randomized to either chemotherapy (CT) + placebo (P) → P or CT + BEV → BEV. Results: After adjusting for prognostic factors, SFA was not associated with the overall hazard of death (p = 0.981). There was a non-significant 0.1% (p = 0.062) increase in hazard of death associated with a unit increase in VFA. When comparing the treatment HRs for patients who did and did not receive BEV, there was no association with SFA (p = 0.890) or VFA (p = 0.106). A non-significant 0.8% increase in the hazard of death with unit increase in BMI (p = 0.086) was observed. BMI values were not predictive of a longer survival for patients with BEV vs placebo (p = 0.606). Conclusion: Measures of adiposity strongly correlated to one another but were not predictive of efficacy for BEV. VFA is a weak prognostic factor.
| Original language | English (US) |
|---|---|
| Journal | Gynecologic oncology |
| DOIs | |
| State | Accepted/In press - Jan 1 2019 |
Fingerprint
Keywords
- Adiposity
- Epithelial ovarian cancer
- NRG
- Prognostic biomarkers
ASJC Scopus subject areas
- Oncology
- Obstetrics and Gynecology
Cite this
Measurements of adiposity as prognostic biomarkers for survival with anti-angiogenic treatment in epithelial ovarian cancer : An NRG Oncology/Gynecologic Oncology Group ancillary data analysis of GOG 218. / Wade, K. N.Slaughter; Brady, M. F.; Thai, T.; Wang, Y.; Zheng, B.; Salani, R.; Tewari, K. S.; Gray, H. J.; Bakkum-Gamez, Jamie N; Burger, R. A.; Moore, K. N.; Bookman, M. A.
In: Gynecologic oncology, 01.01.2019.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Measurements of adiposity as prognostic biomarkers for survival with anti-angiogenic treatment in epithelial ovarian cancer
T2 - An NRG Oncology/Gynecologic Oncology Group ancillary data analysis of GOG 218
AU - Wade, K. N.Slaughter
AU - Brady, M. F.
AU - Thai, T.
AU - Wang, Y.
AU - Zheng, B.
AU - Salani, R.
AU - Tewari, K. S.
AU - Gray, H. J.
AU - Bakkum-Gamez, Jamie N
AU - Burger, R. A.
AU - Moore, K. N.
AU - Bookman, M. A.
PY - 2019/1/1
Y1 - 2019/1/1
N2 - Objective: Adiposity has been hypothesized to interfere with the activity of bevacizumab (BEV), an anti-angiogenic agent. Measurements of adiposity, BMI, surface fat area (SFA), and visceral fat area (VFA) were investigated as prognostic of oncologic outcomes among patients treated with chemotherapy, with or without BEV, on GOG 218, a prospective phase III trial. Method: Pretreatment computed tomography (CT) for 1538 GOG 218 participants were analyzed. Proportional hazards models assessed association between adiposity and overall survival (OS) adjusted for other prognostic factors. The predictive value of adiposity as a function of BEV treatment was assessed in 1019 patients randomized to either chemotherapy (CT) + placebo (P) → P or CT + BEV → BEV. Results: After adjusting for prognostic factors, SFA was not associated with the overall hazard of death (p = 0.981). There was a non-significant 0.1% (p = 0.062) increase in hazard of death associated with a unit increase in VFA. When comparing the treatment HRs for patients who did and did not receive BEV, there was no association with SFA (p = 0.890) or VFA (p = 0.106). A non-significant 0.8% increase in the hazard of death with unit increase in BMI (p = 0.086) was observed. BMI values were not predictive of a longer survival for patients with BEV vs placebo (p = 0.606). Conclusion: Measures of adiposity strongly correlated to one another but were not predictive of efficacy for BEV. VFA is a weak prognostic factor.
AB - Objective: Adiposity has been hypothesized to interfere with the activity of bevacizumab (BEV), an anti-angiogenic agent. Measurements of adiposity, BMI, surface fat area (SFA), and visceral fat area (VFA) were investigated as prognostic of oncologic outcomes among patients treated with chemotherapy, with or without BEV, on GOG 218, a prospective phase III trial. Method: Pretreatment computed tomography (CT) for 1538 GOG 218 participants were analyzed. Proportional hazards models assessed association between adiposity and overall survival (OS) adjusted for other prognostic factors. The predictive value of adiposity as a function of BEV treatment was assessed in 1019 patients randomized to either chemotherapy (CT) + placebo (P) → P or CT + BEV → BEV. Results: After adjusting for prognostic factors, SFA was not associated with the overall hazard of death (p = 0.981). There was a non-significant 0.1% (p = 0.062) increase in hazard of death associated with a unit increase in VFA. When comparing the treatment HRs for patients who did and did not receive BEV, there was no association with SFA (p = 0.890) or VFA (p = 0.106). A non-significant 0.8% increase in the hazard of death with unit increase in BMI (p = 0.086) was observed. BMI values were not predictive of a longer survival for patients with BEV vs placebo (p = 0.606). Conclusion: Measures of adiposity strongly correlated to one another but were not predictive of efficacy for BEV. VFA is a weak prognostic factor.
KW - Adiposity
KW - Epithelial ovarian cancer
KW - NRG
KW - Prognostic biomarkers
UR - http://www.scopus.com/inward/record.url?scp=85070297174&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85070297174&partnerID=8YFLogxK
U2 - 10.1016/j.ygyno.2019.07.020
DO - 10.1016/j.ygyno.2019.07.020
M3 - Article
C2 - 31409486
AN - SCOPUS:85070297174
JO - Gynecologic Oncology
JF - Gynecologic Oncology
SN - 0090-8258
ER -